Identification of 2,6-xylidine as a major lidocaine metabolite in human liver slices

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1167-1173

  Parker, R J ^a   Collins, J M ^a   Strong, J M ^a  

^a OTR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; DEETHYLLIDOCAINE; DRUG METABOLITE; GLYCINE XYLIDIDE; LIDOCAINE; LIVER ENZYME; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CARCINOGENICITY; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG STABILITY; FEMALE; HUMAN; HUMAN TISSUE; INFANT; LIVER HOMOGENATE; LIVER MICROSOME METABOLISM; LIVER SLICE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANILINE COMPOUNDS; BIOTRANSFORMATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIDOCAINE; MODELS, CHEMICAL;

RODENTIA;

EID: 0030459494     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. J. K. Haseman, D. D. Crawford, J. E. Huff, G. A. Boorgman, and E. E. McConnell: Results from 86 2-year carcinogenicity studies conducted by the National Toxicology Program. J. Toxicol. Environ. Health 14, 621-640 (1984).
2. J. B. Keenaghan, and R. N. Boyes: The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs, and man. J. Pharmacol. Exp. Ther. 180, 459-463 (1972).
3. R. T. Coutts, G. A. Torok-Both, Y. K. Tam, L. V. Chu, and F. M. Pasutto: In vivo metabolism of lidocaine in the rat. Isolation of urinary metabolites as pentafluorobenzoyl derivatives and their identification by combined gas chromatography-mass spectrometry. J. Chromatogr. Biomed. Appi 421, 267-280 (1987).
4. Y. K. Tam, S. R. Tawfik, and R. T. Coutts: High-performance liquid chromatography of lidocaine and nine of its metabolites in human plasma and urine. J. Chromatogr. Biomed. Appl. 423, 199-206 (1987).
5. G. D. Breck, and W. F. Trager: Oxidative N-dealkylation: a Mannich intermediate in the formation of a new metabolite of lidocaine in man. Science 172, 544-546 (1971).
6. S. D. Nelson, W. A. Garland, G. D. Breck, and W. F. Trager: Quantification of lidocaine and several metabolites utilizing chemical-ionization mass spectrometry and stable isotope labeling. J. Pharm. Sci. 66, 1180-1189 (1977).
7. C. von Bahr, I. Hedlund, B. Karlen, D. Backstrom, and H. Grasdalen: Evidence for two catalytically different binding sites of liver microsomal P-450: importance for species differences in oxidation pattern of lidocaine. Acta Pharmacol. Toxicol. 41, 39-48 (1977).
8. T. Suzuki, S. Fujita, and R. Kawai: Precursor-metabolite interaction in the metabolism of lidocaine. J. Pharm. Sci. 73, 136-138 (1984).
9. R. Kawai, S. Fujita, and T. Suzuki: Simultaneous quantitation of lidocaine and its four metabolites by high-performance liquid chromatography: application to studies on in vitro and in vivo metabolism. J. Pharm. Sci. 74, 1219-1224 (1985).
10. M. J. Bargetzi, T. Aoyoma, F. J. Gonzalez, and U. A. Meyer: Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46, 521-527 (1989).
11. S. Imaioka, K. Enomoto, Y. Oda, A. Asada, M. Fujimori, T. Shimada, S. Fujita, P. Guengerich, and Y. Funae: Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255, 1385-1391 (1990).
12. Y. Masubuchi, J. Araki, S. Narimatsu, and T. Suzuki: Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein. Biochem. Pharmacol. 43, 2551-2557 (1992).
13. Y. Oda, S. Imaoka, Y. Nakahira, A. Asada, M. Fujimori, S. Fujita, and Y. Funae: Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isoenzymes. Biochem. Pharmacol. 38, 4439-4444 (1989).
14. P. Olinga, M. T. Merema, D. K. F. Meijer, M. J. H. Slooff, and G. M. M. Groothuis: Human liver slices express the same lidocaine biotransformation rate as isolated human hepatocytes. ATLA 21, 466-468 (1994).
15. Y. K. Tam, M. Yau, R. Berzins, P. R. Montgomery, and M. Gray: Mechanisms of lidocaine kinetics in the isolated perfused rat liver. I. Effects of continuous infusion. Drug Metab. Dispos. 15, 12-16 (1987).
16. B. A. Saville, M. R. Gray, and Y. K. Tam: Mechanisms of lidocaine kinetics in the isolated perfused rat liver. II. Kinetics of steady state elimination. Drug Metab. Dispos. 15, 17-21 (1987).
17. M. R. Gray, B. A. Saville, and Y. K. Tam: Mechanisms of lidocaine kinetics in the isolated perfused rat liver. III. Evaluation of liver models for time-dependent behavior. Drug Metab. Dispos. 15, 22-26 (1987).
18. R. C. Kammerer, and D. A. Schmitz: Lidocaine metabolism by rabbit-liver homogenate and detection of a new metabolite. Xenobiotica 16, 681-690 (1986).
19. 14C]-2,6-dimethylaniline to DNA of rat liver and ethmoid turbinate. J. Toxicol. Environ. Health 27, 85-94 (1989).
20. C. R. Short, C. King, P. W. Sistrunk, and K. M. Kerr: Subacute toxicity of several ring-substituted dialkylanilines in the rat. Fundam. Appl. Toxicol. 3, 285-292 (1983).
21. G. Magnusson, N. O. Bodin, and E. Hansson: Hepatic changes in dogs and rats induced by xylidine isomers. Acta Pathol. Microbiol. Scand. 79, 639-648 (1971).
22. J. Weinberg, and V. E. Sahini: Xylidine isomers. 7. Structure-hepatotoxic activity relationships of some xylidines. J. Theoret. Biol. 88, 153-159 (1981).
23. R. T. Coutts, G. A. Torok-Both, Y. K. Tam, L. V. Chu, and F. M. Pasutto: Acetylation and pentafluorobenzoylation of lidocaine metabolites in aqueous solution and identification of derivatives by combined gas chromatography/mass spectrometry. Biomed. Mass Spectrom. 14, 173 (1987).
24. Y. K. Tam, J. Ke, R. T. Coutts, D. G. Wyse, and M. R. Gray: Quantification of three lidocaine metabolites and their conjugates. Pharm. Res. 7, 504-507 (1990).
25. R. W. Sallie, J. M. Tredger, and R. Williams: Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX). Biopharm. Drug Dispos. 13, 555-558 (1992).
26. K. Tanaka, O. Yutaka, A. Asada, M. Fujimori, and Y. Funae: Metabolism of lidocaine by rat pulmonary cytochrome P450. Biochem. Pharmacol. 47, 1061-1066 (1994).